Edition:
United States

StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

0.40USD
12:53pm EDT
Change (% chg)

$-0.03 (-6.05%)
Prev Close
$0.43
Open
$0.43
Day's High
$0.47
Day's Low
$0.40
Volume
164,800
Avg. Vol
78,462
52-wk High
$7.56
52-wk Low
$0.33

Latest Key Developments (Source: Significant Developments)

StemCells announces 1-for-12 reverse stock split
Monday, 9 May 2016 02:43pm EDT 

StemCells Inc : StemCells, inc. Announces 1-for-12 reverse stock split . Trading common stock on Nasdaq Capital Market will continue, on a split-adjusted basis, on may 9, 2016 Further company coverage: [STEM.O] (Bengaluru Newsroom; +1 646 223 8780; ).  Full Article

Stemcells announces 1-for-12 reverse stock split
Friday, 6 May 2016 12:49pm EDT 

Stemcells Inc: Announces 1-for-12 reverse stock split .Trading of common stock on Nasdaq capital market will continue, on a split-adjusted basis, on May 9, 2016.  Full Article

StemCells, Inc announces pricing of public offering to raise $8.1 mln
Wednesday, 9 Mar 2016 09:24am EST 

StemCells, Inc:Announces pricing of public offering to raise $8.1 million.Public offering price of $0.30 for one share, a series a warrant to purchase 0.50 shares, series b warrant to purchase 0.75 shares.Says the series b warrants have an exercise price of $0.42 per share.Says series a warrants have an exercise price of $0.30 per share, are exercisable immediately.  Full Article

StemCells Inc To incur restructuring charges in Q1 - Reuters
Wednesday, 23 Dec 2015 08:41am EST 

StemCells Inc:Drug developer's shares STEM.O down 13.27 pct at 41 cents premarket.Suspends mid-stage study on eye drug while it seeks partner (Full Story).Cuts total workforce by 25 pct, as of Dec 31, 2014 the company had 69 employees.Will incur restructuring charges of about $400,000 in Q1 2016.Will use company's resources for its lead treatment for chronic spinal cord injury.  Full Article

StemCells Inc announces closing of $25 million public offering
Wednesday, 29 Apr 2015 04:05pm EDT 

StemCells:Closes its previously announced offering of common stock and warrants.Company sold a total of 35,715,000 shares and warrants to acquire 26,786,250 shares of common stock at a public offering price of $0.70 per unit for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock.Company also issued warrants to purchase an additional 4,017,938 shares of common stock pursuant to the exercise of the underwriters' option to acquire additional warrants to cover over-allotments.Company received total proceeds, net of offering expenses, underwriting discounts and commissions, of about $23.35 mln.Warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance.If the warrants are exercised in full, StemCells, Inc. will receive additional proceeds of approximately $26.2 million.Underwriters have a 30-day option to purchase up to an additional 5,357,250 shares of common stock to cover over-allotments.Maxim Group LLC acted as sole book-running manager and Chardan Capital Markets, LLC acted as co-manager for the offering.Meyers Associates, L.P. and IFS Securities, Inc. acted as financial advisors for the offering.  Full Article

StemCells announces pricing of public offering to raise $25 million
Friday, 24 Apr 2015 09:25am EDT 

StemCells:Prices an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock.Warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance.Expects to receive gross proceeds of about $25.0 mln, before deducting underwriting discounts and commissions and other estimated offering expenses.Company has also granted the underwriters a 30 day option to purchase up to an additional 5,357,250 shares of common stock and/or warrants to purchase up to an additional 4,017,938 shares of common stock to cover over-allotments, if any.Offering is expected to close on or about April 29, 2015, subject to customary closing conditions.Maxim Group LLC is acting as sole book-running manager and Chardan Capital Markets is acting as co-manager for the offering.  Full Article

StemCells Inc appoints Ian Massey as President and Chief Operating Officer
Tuesday, 24 Mar 2015 10:34am EDT 

StemCells Inc:Says Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23.Says in this new role, Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality assurance activities.  Full Article

TAKARA BIO to acquire stem cell research product related assets from StemCells
Monday, 10 Nov 2014 01:00am EST 

TAKARA BIO INC:To acquire stem cell research product related assets including intellectual properties, from StemCells Inc.To start manufacture and sale of cell research product from Jan. 2015.  Full Article

StemCells Inc initiates phase II clinical trial in Cervical Spinal Cord Injury
Tuesday, 7 Oct 2014 08:00am EDT 

StemCells Inc:Says it has initiated its Pathway Study, a Phase II proof of concept clinical trial using its HuCNS-SC platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI).Says the trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).Says the primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders.Says the trial will follow the patients for one year from the time of enrollment.  Full Article

StemCells to wind down operations after ending mid-stage study

StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent.